The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal

S Brissos, MR Veguilla, D Taylor… - Therapeutic …, 2014 - journals.sagepub.com
Despite their widespread use, long-acting injectable (LAI) antipsychotics (APs) are often
regarded with some negativity because of the assumption of punishment, control and …

Early detection and preventive intervention in schizophrenia: from fantasy to reality

JA Lieberman, SA Small… - American Journal of …, 2019 - Am Psychiatric Assoc
Scientific progress in understanding human disease can be measured by the effectiveness
of its treatment. Antipsychotic drugs have been proven to alleviate acute psychotic symptoms …

Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial

KL Subotnik, LR Casaus, J Ventura, JS Luo… - JAMA …, 2015 - jamanetwork.com
Importance Long-acting, injectable, second-generation antipsychotic medication has
tremendous potential to bring clinical stability to persons with schizophrenia. However, long …

Myelination, oligodendrocytes, and serious mental illness

V Haroutunian, P Katsel, P Roussos, KL Davis… - Glia, 2014 - Wiley Online Library
Historically, the human brain has been conceptually segregated from the periphery and
further dichotomized into gray matter (GM) and white matter (WM) based on the whitish …

Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia

G Kaplan, J Casoy, J Zummo - Patient preference and adherence, 2013 - Taylor & Francis
Schizophrenia is a debilitating chronic disease that requires lifelong medical care and
supervision. Even with treatment, the majority of patients relapse within 5 years, and suicide …

Long-term continuity of antipsychotic treatment for schizophrenia: a nationwide study

JM Rubio, H Taipale, A Tanskanen… - Schizophrenia …, 2021 - academic.oup.com
Schizophrenia often requires long-term treatment with antipsychotic medication. This study
aims to measure the continuity of antipsychotic treatment over the course of illness in …

The effect of longer dosing intervals for long-acting injectable antipsychotics on outcomes in schizophrenia

R Milz, C Benson, K Knight, J Antunes… - Neuropsychiatric …, 2023 - Taylor & Francis
Medication nonadherence in schizophrenia can have serious implications including
relapses and hospitalization. Long-acting injectable (LAI) antipsychotics require fewer …

[HTML][HTML] The early longitudinal course of cognitive deficits in schizophrenia

KH Nuechterlein, J Ventura, KL Subotnik… - The Journal of clinical …, 2014 - psychiatrist.com
Cognitive impairment is a core feature of schizophrenia. However, the longitudinal course
and pattern of this impairment, and its relationship to functional outcome, are not fully …

Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics

S Heres, M Lambert, R Vauth - European Psychiatry, 2014 - cambridge.org
The use of long-acting injectable antipsychotics (LAIs) in schizophrenia is usually restricted
to patients in long-term treatment, who prefer them to oral antipsychotics, and to patients with …

Alterations of myelin content in Parkinson's disease: a cross-sectional neuroimaging study

DC Dean III, J Sojkova, S Hurley, S Kecskemeti… - PloS one, 2016 - journals.plos.org
Alterations to myelin may be a core pathological feature of neurodegenerative diseases.
Although white matter microstructural differences have been described in Parkinson's …